Description
Proteomics: A Promising Approach for Cancer Research Volume 2 Proteome signaling dysregulation in cancer, therapeutic interventions, and future perspectives provides an updated overview of scientific knowledge, achievements, and findings in the field of cancer proteomics. The field of cancer proteomics is very dynamic, with emerging trends specifically related to clinical solutions. The book content was developed to help readers get up to speed on the topic and easily apply learnings into research or clinical practice.Volume 2 covers proteome signaling, their dysregulation to therapeutics options and future prospects in 17 different signaling pathways. It capitalizes the enormous interest in proteomics among academics and gives new viewpoints on this topic in cancer treatment. It is a valuable resource for cancer researchers, oncologists, graduate students, and members of biomedical field who are interested in the potential of proteomics in cancer research and treatment.- Provides up to date information on current cancer proteomics research developed globally- Presents from basic research aspects to clinical implications of proteomics on cancer diagnosis and potential treatments- Discusses challenges and future developments of the field to leverage further research and applicability in clinical setting- Contains exclusive information about research on proteome signaling dysregulation in cancer and therapies globally- Includes recent details which will be the prerequisite requirement for any researcher who wants to work on cancer proteomics, proteome signaling dysregulation and therapeutics
Table of Contents
1. Breast cancer: JAK/STAT signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives2. Colorectal cancer: Notch signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives3. Lung cancer: Akt/PKB signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives4. Leukemia: Hedgehog signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives5. Gastric cancer: AMPK signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives6. Pancreatic cancer: Wnt signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives7. Cervical cancer: TGFβ signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives8. Ovarian cancer: VEGF signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives9. Brain cancer: Hippo signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives10. Endometrial cancer: cAMP-dependent signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives11. Lymphoma: TLR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives12. Thyroid cancer: MAPK/Erk signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives13. Kidney cancer: mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives14. Liver cancer: Insulin signal transduction pathway dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives15. Bladder cancer: PI3K/Akt/mTOR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives16. Skin cancer: Eph/ephrin signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives17. Esophageal Cancer: Nodal signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
